BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 10997809)

  • 1. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
    De Pas T; de Braud F; Danesi R; Sessa C; Catania C; Curigliano G; Fogli S; del Tacca M; Zampino G; Sbanotto A; Rocca A; Cinieri S; Marrocco E; Milani A; Goldhirsch A
    Ann Oncol; 2000 Jul; 11(7):821-7. PubMed ID: 10997809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.
    De Pas T; Putzu C; Curigliano G; Noberasco C; Boselli S; Catania C; Orlando L; Milani A; Spaggiari L; de Braud F
    Lung Cancer; 2006 Dec; 54(3):359-64. PubMed ID: 17028052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
    Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
    Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
    Fogli S; Danesi R; De Braud F; De Pas T; Curigliano G; Giovannetti G; Del Tacca M
    Ann Oncol; 2001 Nov; 12(11):1553-9. PubMed ID: 11822754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
    Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
    Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
    Lorusso V; Crucitta E; Panza N; Silvestris N; Guida M; Carpagnano F; Mancarella S; Sambiasi D; De Lena M
    Ann Oncol; 2002 Dec; 13(12):1862-7. PubMed ID: 12453853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
    Gillenwater HH; Stinchcombe TE; Qaqish BF; Tyann M; Hensing TA; Socinski MA
    Lung Cancer; 2005 Mar; 47(3):413-9. PubMed ID: 15713525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
    Favaretto A; Ceresoli GL; Paccagnella A; Barbieri F; Bearz A; Ghiotto C; Oniga F; Schiavon S; Frustaci S; Villa E
    Ann Oncol; 2000 Nov; 11(11):1421-6. PubMed ID: 11142482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer.
    Rebattu P; Quantin X; Ardiet C; Morere JF; Azarian MR; Schuller-Lebeau MP; Pujol JL
    Lung Cancer; 2001; 33(2-3):277-87. PubMed ID: 11551423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.
    Giaccone G; Smit EF; van Meerbeeck JP; Splinter T; Golding RP; Pinedo HM; Laan D; van Tinteren H; Postmus PE
    Ann Oncol; 2000 Jan; 11(1):109-12. PubMed ID: 10690398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
    Koizumi T; Yoshiike F; Inou H; Hatayama O; Sasabayashi M; Tsushima K; Yamamoto H; Hayasaka M; Kubo K
    Med Oncol; 2004; 21(2):133-7. PubMed ID: 15299185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
    Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
    Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
    Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New triplet chemotherapy combination with carboplatin, paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer: a phase II study.
    Illiano A; Barletta E; De Marino V; Battiloro C; Barzelloni M; Scognamiglio F; Rossi N; Zampa G; De Bellis M; Gridelli C
    Anticancer Res; 2000; 20(5C):3999-4003. PubMed ID: 11268491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.